>
网站首页期刊介绍通知公告编 委 会投稿须知电子期刊广告合作联系我们
最新消息:
培美曲塞+顺铂方案同步放疗治疗局部晚期非鳞非小细胞肺癌的临床观察
作者:沈月  夏建洪  王珂  周立庆 
单位:徐州医科大学附属淮安医院 放疗科, 江苏 淮安 223002
关键词:局部晚期非鳞非小细胞肺癌 同步化疗 调强放疗 近期疗效 安全性 
分类号:R734.2;R815.6
出版年·卷·期(页码):2017·36·第六期(912-915)
摘要:

目的:探讨培美曲塞+顺铂方案同步放疗对局部晚期非鳞非小细胞肺癌的近期疗效及安全性。方法:将68例非鳞非小细胞肺癌患者随机分为观察组与对照组,观察组采用培美曲塞+顺铂方案化疗同步调强放疗,对照组采用依托泊苷+顺铂方案化疗同步调强放疗,所有患者后续按原方案化疗2个周期,随访3个月,比较两组的近期疗效及安全性。结果:观察组有效率及疾病控制率分别为76.47%、94.12%,均高于对照组,差异有统计学意义(P<0.05);观察组白细胞减少、恶心呕吐发生率均低于对照组,差异有统计学意义(P<0.05)。血红蛋白减少、血小板减少及肝功能损害的发生率两组均在50%以下,差异均无统计学意义(P>0.05)。结论:培美曲赛+顺铂方案同步放疗对局部晚期非鳞非小细胞肺癌近期疗效明确,患者可耐受,可作为一线可选方案。

Objective: To study the short-term efficiency and safety of pemetrexed plus cisplatin concurrent radiotherapy for locally advanced non-squamous-non-small cell lung cancer.Methods: Sixty-eight cases of non-squamous-non-small-cell lung cancer were divided into the observation group and the control group randomly. The observation group were given pemetrexed plus cisplatin concurrent intensity modulated radiotherapy, while the control group were given etoposide plus cisplatin concurrent intensity modulated radiotherapy. Then all the patients received sequential chemotherapy following previous regimens and followed-up for 3 months. The short-term efficiency and safety was compared between the two groups. Results: Efficiency rate and disease control rate of the observation group were 76.47% and 94.12% respectively, higher than those of the control group(52.94% and 76.47%), the difference were statistically significant(P<0.05). The incidence of leukocytopenia and nausea and vomiting of the observation group were 85.29% and 58.82%, lower than those of the control group, with statistical difference(P<0.05). The incidence of decreased hemoglobin, thrombocytopenia and liver damage in the two groups were all below 50%, without statistical difference(P>0.05).Conclusion: The short-term efficiency and safety of pemetrexed plus cisplatin concurrent radiotherapy for locally advanced non-squamous-non-small cell lung cancer are certain, they can be selected as first-line regimen.

参考文献:

[1] WANG Z.Selection of chemotherapy for non-small cell lung cancer is facilitated by new therapeutic strategies[J].Int J Clin Exp Med,2014,7(11):3833-3842.
[2] YUN M,KIM E O,LEE D,et al.Melatoninsensitizes H1975 non-small cell lung cancer cells harboring a T790M-targetedepidermal growth factor receptor mutation to the tyrosine kinase inhibitor gefitinib[J].Cell Physiol Biochem,2014,34(3):865-872.
[3] 蒋军,黄荣,邓燕明,等.培美曲塞联合顺铂在局部晚期肺腺癌同步放化疗中的临床研究[J].国际医药卫生导报,2013,19(21):3268-3273.
[4] MOORCRAFT S Y.Introduction to clinical problems in Oncology[M]//MOORCRAFT S Y,LEE D,CUNNINGHAM D,et al.Clinical problems in oncology:A practical guide to management.New Jersey:Wiley-Blackwell,2014:1-12.
[5] 陈兰,范娟.治疗非小细胞肺癌的临床研究进展[J].西南军医,2014,16(3):325-327.
[6] AHN J S,AHN Y C,KIM J H,et al.Multinational randomized phase Ⅲ trial with or without consolidation chemotherapy using docetaxel and cisplatin after concurrent chemoradiation in inoperable stage Ⅲ non-small-cell lung cancer:KCSG-LU05-04[J].J Clin Oncol,2015,33(24):2660-2666.
[7] 李金凯,葛小林,王沛沛,等.利用4D锥形束CT研究肺癌放疗的靶区外放范围[J].东南大学学报:医学版,2015,34(4):609-612.
[8] 孟丽娟,王俊,刘福银,等.老年晚期非小细胞肺癌单药二线培美曲赛或多西他赛化疗的临床观察[J].实用老年医学,2010,24(1):66-68.
[9] HWANG K E,KIM Y S,HWANG Y R,et al.Enhanced apoptosis by pemetrexed and simvastatin in malignant mesothelioma and lung cancer cells by reactive oxygen species-dependent mitochondrial dysfunction and Bim induction[J].Int J Oncol,2014,45(4):1769-1777.
[10] 包桂红.培美曲塞单药或联合化疗治疗晚期复发性非小细胞肺癌60例分析[J].中国医药指南,2016,14(2):149.
[11] ZHENG Y,FANG W,DENG J,et al.Sequential treatment of icotinib after first-line pemetrexed in advanced lung adenocarcinoma with unknown EGFR gene status[J].J Thorac Dis,2014,6(7):958-964.
[12] KIM Y H,NISHIMURA T,OZASA H.Phase Ⅱ study of pemetrexed and erlotinib in pretreated nonsquamous,non-small-cell lung cancer patients without an EGFR mutation[J].Chemotherapy,2014,59(6):414-419.

服务与反馈:
文章下载】【发表评论】【查看评论】【加入收藏
提示:您还未登录,请登录!点此登录
您是第 143242 位访问者


copyright ©《东南大学学报(医学版)》编辑部
联系电话:025-87232483 83272481
电子邮件:
bjb@pub.seu.edu.cn

苏ICP备09058364